# Zimmer Biomet (ZBH) Financial Model Free Excel 3-statement financial model and company analysis for Zimmer Biomet. - Canonical: https://finamodel.com/companies/zimmer-biomet - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/ZBH.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario analysis framework for Zimmer Biomet to help an equity research analyst or portfolio manager forecast earnings, assess the impact of recent acquisitions, and determine a fair value price target. ## Company Overview Zimmer Biomet Holdings, Inc. is a global medical technology leader specialising in musculoskeletal healthcare and orthopaedics. The company designs, manufactures, and markets orthopaedic reconstructive products, sports medicine, biologics, extremities, and trauma products, alongside integrated digital and robotic technologies. Business segments include: * Knees (approximately 40% of revenue) * Hips (approximately 25% of revenue) * S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) (approximately 25% of revenue) * Other (Technology & Data, Bone Cement and Surgical) (approximately 10% of revenue) Key geographies are the Americas (predominantly the United States, representing over 55% of total sales), EMEA, and Asia Pacific. The business model is asset-heavy manufacturing combined with high intellectual property and R&D investment, relying on direct sales forces and independent distributors to place products in hospitals. Zimmer Biomet holds a top-tier competitive position globally in large joint reconstruction alongside Stryker and Johnson & Johnson (DePuy Synthes). Recent major events include the March 2022 spin-off of its spine and dental business (ZimVie) and the April 2025 acquisition of Paragon 28 to bolster its extremities portfolio. ## Revenue Deep Dive ### Knees * Segment name: Knees * Revenue driver formula: Total Knee Procedures x Average Selling Price (ASP) * Historical growth rate: 3% to 5% CAGR * Key growth levers and headwinds: Driven by aging demographics, obesity trends, and the adoption of the ROSA Robotics system which pulls through implant sales. Headwinds include hospital staffing shortages and pricing pressure from healthcare systems. * Pricing dynamics: Highly competitive, typically experiencing low single-digit annual price erosion offset by volume growth and mix shift to premium products. * Revenue recognition notes: Recognised upon consumption during surgery (for consigned inventory) or upon shipment to the hospital. * Seasonality: Q4 is historically the strongest quarter due to patients scheduling elective surgeries before year-end to utilise met deductibles. ### Hips * Segment name: Hips * Revenue driver formula: Total Hip Procedures x Average Selling Price (ASP) * Historical growth rate: 1% to 3% CAGR * Key growth levers and headwinds: Growth is supported by new technologies like the iodine-treated hip implants to prevent infection. Headwinds include a highly mature market and pricing erosion. * Pricing dynamics: Contractual pricing with hospital purchasing groups, subject to annual price down-ticks. * Revenue recognition notes: Similar to Knees, largely based on surgical consumption of consigned inventory. * Seasonality: Strongest in Q4, weakest in Q3 due to summer holidays reducing elective procedure volumes. ### S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) * Segment name: S.E.T. * Revenue driver formula: Procedure Volume x Product ASP * Historical growth rate: 6% to 15% CAGR (boosted by recent M&A) * Key growth levers and headwinds: The fastest-growing segment, heavily driven by the shift of procedures to Ambulatory Surgery Centres (ASCs) and the April 2025 acquisition of Paragon 28. * Pricing dynamics: Less pricing pressure than large joints, with premium pricing for innovative extremity implants. * Revenue recognition notes: Standard point-of-sale or surgical consumption. * Seasonality: Trauma is less seasonal than elective joints, but sports medicine peaks in Q4. ### Other (Technology & Data, Bone Cement and Surgical) * Segment name: Other * Revenue driver formula: Capital Equipment Placements x Unit Price + Recurring Consumables * Historical growth rate: 4% to 6% CAGR * Key growth levers and headwinds: Driven by the ZBEdge platform and ROSA robot placements. Capital equipment sales are sensitive to hospital capex budgets. * Pricing dynamics: High upfront capital cost with negotiated service contracts. * Revenue recognition notes: Capital equipment is recognised upon installation and acceptance, while service contracts are deferred and recognised over time. * Seasonality: Heavy Q4 weighting as hospitals exhaust annual capital budgets. ## Cost Structure ### Variable Costs / COGS * COGS includes raw materials (titanium, cobalt-chrome, plastics), direct manufacturing labour, overhead, royalties, and freight. It also includes depreciation of surgical instruments placed in hospitals. * Gross margin range: 61% to 64% on a GAAP basis (impacted by inventory step-ups and tariffs), but 71% to 73% on an adjusted non-GAAP basis. * Key input costs and commodity exposures: Titanium and specialized plastics, though manufacturing variances and supply chain logistics are larger drivers. * How COGS scales with revenue: Largely linear, but subject to operating leverage on fixed manufacturing overheads. ### Operating Expenses * R&D: Typically 5% to 6% of revenue. Covers clinical trials, regulatory submissions, and engineering for new implants and robotics. * SG&A: Typically 38% to 41% of revenue. Heavily weighted towards sales commissions, marketing, and medical education. * Depreciation & Amortisation: Significant amortisation of acquired intangible assets (often 6% to 8% of revenue) due to historical M&A. * Stock-Based Compensation: Typically 1% to 2% of revenue. * Restructuring / one-time charges: Frequent and material. The company regularly reports restructuring charges, acquisition integration costs, and European Medical Device Regulation (MDR) compliance costs. ### Margin Profile * Gross margin: 71% to 73% (Adjusted). * EBITDA margin: 33% to 36% (Adjusted). * Operating margin: 27% to 29% (Adjusted). * Net margin: 18% to 21% (Adjusted). * Margin trend: Management is targeting margin expansion through a dedicated U.S. salesforce transformation and manufacturing footprint optimisation, though 2026 guidance suggests a temporary 50 basis point contraction due to M&A integration. ## Balance Sheet Structure * Total assets: Approximately $21 to $23 billion. * Key asset categories: Goodwill, Intangible Assets, Inventory, and Property, Plant & Equipment (PP&E). * Goodwill & intangibles as % of total assets: Very high, typically 50% to 55%, reflecting the legacy Biomet merger and recent acquisitions like Paragon 28. * Working capital profile: * Days Sales Outstanding (DSO): 55 to 65 days. * Days Inventory Outstanding (DIO): 250 to 300 days. Orthopaedic companies must hold massive inventory (various sizes of implants) to service surgeries. * Days Payable Outstanding (DPO): 40 to 50 days. * Net working capital as % of revenue: High, typically 25% to 30% of revenue. * Is working capital positive or negative? Positive. The company requires significant working capital to fund inventory growth. * PP&E: Includes manufacturing facilities and a massive pool of surgical instruments deployed to hospitals (capitalised and depreciated over 3 to 5 years). * Right-of-use assets / operating leases: Material but not a dominant asset class, representing standard facility leases. ## Capital Expenditure & Investment * Capex as % of revenue: 5% to 7%. * Maintenance capex vs. growth capex: Approximately 40% maintenance (facility upkeep) and 60% growth (new surgical instrument sets for product launches). * Major capex programmes underway or planned: Investment in ZBEdge digital infrastructure and manufacturing automation. * Capitalised software / development costs if material: Moderate, related to internal ERP systems and digital health applications. * M&A pattern: Serial bolt-on acquirer with occasional medium-sized deals (e.g., Paragon 28 in 2025, Embody in 2023). * Typical acquisition multiple paid: 4x to 6x forward revenue for high-growth extremity or digital assets. ## Debt & Capital Structure * Total debt: Approximately $7.5 billion, with Net Debt around $6.9 billion (as of year-end 2025). * Debt/EBITDA ratio: Current is approximately 2.3x to 2.5x, with a long-term target of 2.0x. * Credit rating: Investment grade (typically BBB/Baa2). * Key debt instruments: Senior unsecured notes and a multi-currency revolving credit facility. * Maturity profile: Staggered bond maturities over the next 10 to 15 years. * Interest rate profile: Predominantly fixed-rate bonds, with a weighted average cost of debt around 3.5% to 4.5%. * Covenants: Standard investment-grade covenants, primarily interest coverage and leverage maximums. * Share repurchase programme: Highly active. A $1.5 billion programme was authorised in February 2026, following a $2.0 billion programme in 2024. * Dividend policy: Quarterly dividend of $0.24 per share ($0.96 annualised), representing a yield of roughly 0.8% to 1.0% and a payout ratio of 10% to 15% of adjusted earnings. ## Cash Flow Characteristics * Operating cash flow conversion: OCF / Net Income is typically strong, often 1.5x to 2.0x on a GAAP basis due to heavy non-cash amortisation. * Free cash flow margin: 12% to 15% (FCF / Revenue). 2025 FCF was $1.172 billion. * Major non-cash items that bridge net income to OCF: Depreciation, amortisation of acquired intangibles, stock-based compensation, and inventory step-up charges. * Working capital cash flow impact: Inventory builds are a persistent use of cash, especially ahead of major new product launches. * Capex intensity: Moderate, driven heavily by the need to manufacture and deploy surgical instruments. * Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than the GAAP rate due to the tax deductibility of goodwill amortisation and R&D credits. Adjusted effective tax rate is typically 16% to 18%. ## Sheet Structure 1. **Assumptions**: Hardcoded drivers for macroeconomic factors, segment growth rates, pricing, margins, working capital days, and capital allocation. 2. **Scenarios**: Scenario manager (Base, Bull, Bear) toggling key revenue and margin drivers. 3. **Revenue_Build**: Detailed build of revenue by segment (Knees, Hips, S.E.T., Other) and by geography (Americas, EMEA, Asia Pacific) using volume and price assumptions. 4. **Income_Statement**: GAAP and Non-GAAP (Adjusted) P&L. Must include specific lines for Intangible Amortisation, Restructuring, and Acquisition-related costs. 5. **Balance_Sheet**: Standard assets, liabilities, and equity. Must break out Inventory clearly and separate Intangibles from Goodwill. 6. **Cash_Flow**: Indirect method starting from Net Income. Must include specific add-backs for Amortisation and Restructuring. 7. **Debt_Schedule**: Tranche-by-tranche bond maturity schedule, revolver drawdowns, and interest expense calculation. 8. **Working_Capital**: Schedules for Accounts Receivable, Inventory (crucial for this company), and Accounts Payable based on days outstanding. 9. **Depreciation_Amortisation**: Waterfall schedules for PP&E (including surgical instruments) and Intangible Assets. 10. **Shareholders_Equity**: Retained earnings roll-forward, dividend payouts, and share repurchase tracking. 11. **Valuation_DCF**: Unlevered free cash flow build, WACC calculation, and terminal value using the perpetuity growth method. 12. **Valuation_Comps**: Trading multiples (EV/EBITDA, P/E) for peers like Stryker, Medtronic, and Smith & Nephew. ## Key Financial Relationships 1. Knees Revenue = Prior Year Knees Revenue x (1 + Knees Volume Growth + Knees Price Impact) 2. Hips Revenue = Prior Year Hips Revenue x (1 + Hips Volume Growth + Hips Price Impact) 3. S.E.T. Revenue = Prior Year S.E.T. Revenue x (1 + Organic S.E.T. Growth) + M&A Revenue Contribution (e.g., Paragon 28) 4. Other Revenue = Prior Year Other Revenue x (1 + Capital Equipment Growth Rate) 5. Total Net Sales = Knees Revenue + Hips Revenue + S.E.T. Revenue + Other Revenue 6. Adjusted Gross Profit = Total Net Sales x Adjusted Gross Margin (historically 72.2%) 7. GAAP Gross Profit = Adjusted Gross Profit - Inventory Step-Up Charges - Restructuring in COGS 8. Adjusted Operating Income = Adjusted Gross Profit - R&D Expense - Adjusted SG&A Expense 9. GAAP Operating Income = Adjusted Operating Income - Intangible Amortisation - Restructuring Charges - Acquisition Costs 10. Inventory Balance = (Total Net Sales x (1 - GAAP Gross Margin)) x (Days Inventory Outstanding / 365) 11. Free Cash Flow = Operating Cash Flow - Capital Expenditures (including surgical instruments) 12. Interest Expense = Average Debt Balance x Weighted Average Interest Rate 13. Share Count = Prior Year Share Count - (Share Repurchase Amount / Average Share Price) + Stock Comp Issuances 14. Adjusted Diluted EPS = Adjusted Net Income / Diluted Share Count ## Cross-Sheet Dependencies * The **Assumptions** sheet feeds growth rates and margins into the **Revenue_Build** and **Income_Statement**. * The **Revenue_Build** feeds Total Net Sales into the **Income_Statement** and drives Accounts Receivable in the **Working_Capital** sheet. * The **Income_Statement** generates Net Income, which is the starting point for the **Cash_Flow** sheet and feeds Retained Earnings on the **Balance_Sheet**. * The **Working_Capital** sheet calculates changes in operating assets and liabilities, feeding the operating section of the **Cash_Flow** sheet. * The **Depreciation_Amortisation** sheet feeds depreciation into COGS/Opex on the **Income_Statement** and adds it back on the **Cash_Flow** sheet, while reducing asset balances on the **Balance_Sheet**. * The **Debt_Schedule** creates a circular reference: Debt balances dictate Interest Expense on the **Income_Statement**, which impacts Net Income and thereby Operating Cash Flow on the **Cash_Flow** sheet, which determines the cash available for debt paydown or revolver borrowing on the **Debt_Schedule**. * The **Cash_Flow** sheet outputs the ending cash balance, which links directly to the **Balance_Sheet** to ensure it balances. ## Sign Convention * Revenues and positive earnings are entered as positive numbers. * Expenses (COGS, SG&A, R&D, Interest, Taxes) on the Income Statement are entered as positive numbers and subtracted in subtotals. * On the Cash Flow statement, cash inflows (e.g., Net Income, Depreciation add-back, increase in Accounts Payable) are positive. * Cash outflows (e.g., Capex, increase in Inventory, dividends paid, share repurchases) are negative. * Contra-asset accounts (like Accumulated Depreciation) are entered as positive numbers and subtracted from gross assets. ## Things Most Likely to Go Wrong 1. Failing to separate GAAP from Non-GAAP (Adjusted) earnings. Zimmer Biomet has massive differences between the two due to acquisition amortisation and restructuring; valuing the company on GAAP EPS will severely understate its true cash-generating power. 2. Underestimating the cash drag of surgical instruments. These are capitalised in PP&E and depreciated, meaning Capex will always be structurally higher than a pure software or asset-light business. 3. Ignoring foreign currency impacts. With over 40% of sales outside the U.S., FX swings can alter reported revenue by 1% to 2% annually. The model must allow for constant currency versus reported growth toggles. 4. Mishandling the Paragon 28 acquisition. The model must account for the inorganic revenue bump in the S.E.T. segment starting in April 2025 and annualising in April 2026. 5. Inventory days are exceptionally high (250+ days). If the model uses a generic 60-day assumption, it will drastically overstate free cash flow generation. 6. Failing to model price erosion. Orthopaedic implants face continuous price down-ticks; volume growth must outpace price erosion just to keep revenue flat. 7. Miscalculating the share count reduction. The company has aggressive buyback programmes ($1.5 billion in 2026); failing to model this will understate EPS growth. 8. Overlooking the seasonality of elective procedures. Q4 is always the strongest cash flow and revenue quarter; quarterly models must reflect this weighting. ## Validation Checks 1. Adjusted Gross Margin should remain in the 71% to 73% band; flag if it deviates outside this range. 2. Adjusted Operating Margin should be between 27% and 29%; flag if the model shows unrealistic margin expansion above 30% without a clear driver. 3. Free Cash Flow must exceed $1.0 billion annually based on recent historical performance. 4. Days Inventory Outstanding (DIO) must remain above 250 days; flag if it drops below 200 days as this is structurally impossible for their business model. 5. Total Assets must equal Total Liabilities plus Shareholders' Equity in every forecasted period. 6. Debt/EBITDA should remain below 3.0x to maintain the investment-grade credit rating. 7. The effective tax rate (Adjusted) should be between 16% and 18%. 8. Dividend payout ratio should remain comfortably below 20% of Adjusted Net Income. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Knees Revenue Growth (Reported) | 4.0 | % | Blended volume growth and price erosion based on 2024/2025 actuals | | Hips Revenue Growth (Reported) | 1.5 | % | Mature market with steady low-single-digit growth | | S.E.T. Revenue Growth (Reported) | 12.0 | % | High growth segment, boosted by Paragon 28 acquisition | | Other Revenue Growth (Reported) | 5.0 | % | Steady capital equipment and robotics placements | | Adjusted Gross Margin | 72.2 | % | Actual reported adjusted gross margin for full-year 2025 | | R&D as % of Sales | 5.5 | % | Historical average required to maintain product pipeline | | Adjusted SG&A as % of Sales | 39.2 | % | Derived from 2025 adjusted operating margin targets | | Adjusted Operating Margin | 27.5 | % | Actual reported adjusted operating margin for full-year 2025 | | Days Sales Outstanding (DSO) | 60 | Days | Based on historical receivables collection patterns | | Days Inventory Outstanding (DIO) | 275 | Days | Reflects heavy inventory requirements for orthopaedic implants | | Days Payable Outstanding (DPO) | 45 | Days | Standard vendor payment terms | | Capex as % of Revenue | 6.0 | % | Historical average, heavily driven by surgical instrument placement | | Effective Tax Rate (Adjusted) | 17.0 | % | Management guidance range for non-GAAP tax rate | | Weighted Average Interest Rate | 4.2 | % | Blended rate on existing senior notes and revolver | | Annual Share Repurchases | 500 | $ Millions | Run-rate assumption based on $1.5B authorisation over 3 years | | Annual Dividend per Share | 0.96 | $ | Based on $0.24 quarterly dividend declared in 2025 | | WACC | 8.0 | % | Standard discount rate for large-cap medical device companies | | Terminal Growth Rate | 2.0 | % | Aligns with long-term GDP and healthcare spending growth | ## Data Sources & Benchmarks * **SEC Filings**: Zimmer Biomet Investor Relations website (investor.zimmerbiomet.com) and SEC EDGAR for 10-K, 10-Q, and 8-K filings. * **Key Peers for Benchmarking**: Stryker (SYK), Medtronic (MDT), Johnson & Johnson (JNJ - DePuy Synthes segment), Smith & Nephew (SNN). * **Industry Data Sources**: Orthopaedic Network News (ONN) for implant pricing and volume data, American Academy of Orthopaedic Surgeons (AAOS) registry data. * **Consensus Estimates**: FactSet or Bloomberg for forward-looking analyst estimates on revenue and adjusted EPS. * **Proprietary Data**: IQVIA or Definitive Healthcare for hospital procedure volumes and capital equipment purchasing trends. ## Sources * Zimmer Biomet Q4 and Full-Year 2025 Earnings Release (February 10, 2026) * Zimmer Biomet Q3 2025 Earnings Release (November 5, 2025) * Zimmer Biomet 2024 Annual Report on Form 10-K (February 25, 2025) * Quartr API Earnings Summaries for Zimmer Biomet 2025 * TradingView SEC 10-K Report Summary for Zimmer Biomet (February 20, 2026) --- ## Frequently asked questions ### What does Zimmer Biomet do? Zimmer Biomet is a global medical technology leader specializing in musculoskeletal healthcare and orthopaedics. The company designs, manufactures, and markets orthopaedic reconstructive products, sports medicine, biologics, extremities, and trauma products, alongside integrated digital and robotic technologies. ### What are Zimmer Biomet's primary revenue segments? Zimmer Biomet generates revenue primarily from its Knees segment, which accounts for approximately 40% of sales. The Hips and S.E.T. (Sports Medicine, Extremities, Trauma) segments each contribute around 25% of total revenue. ### What is the assumed capital expenditure rate in the Zimmer Biomet financial model? In the Zimmer Biomet financial model, capital expenditure (Capex) is assumed to be approximately 2.63% of revenue. This reflects the company's ongoing investment in manufacturing facilities and a massive pool of surgical instruments deployed to hospitals. ### What is the purpose of the Zimmer Biomet financial model? The Zimmer Biomet financial model provides a comprehensive framework for equity valuation and scenario analysis. It helps equity research analysts and portfolio managers forecast earnings, assess the impact of recent acquisitions, and determine a fair value price target. ### Can I download an Excel financial model for Zimmer Biomet? Yes, a comprehensive Excel financial model for Zimmer Biomet is available for download. This model allows users to forecast earnings, assess acquisitions, and perform scenario analysis for the company. ### What are the key balance sheet characteristics of Zimmer Biomet? Zimmer Biomet's balance sheet is characterized by very high goodwill and intangible assets, typically 50% to 55% of total assets, reflecting legacy mergers and recent acquisitions. The company also maintains significant positive net working capital, primarily due to the massive inventory required to service surgeries. [Interactive forecast calculator](https://finamodel.com/companies/zimmer-biomet/forecast)